

New Therapeutic Strategies for Ventricular Remodeling in Acute Myocardial Infarction and Pressure Overload: The Long Way to Heaven

Mariangela Peruzzi^{1*}, MD, Giuseppe Biondi-Zoccai¹, MD, Antonino G.M. Marullo¹, MD, Antonio Barretta¹, MD, Sara Izzo¹, Piergiusto Vitulli¹, and Giacomo Frati^{1,2} MD

¹Department of Medical-Surgical Science and Biotechnologies, Faculty of Pharmacy and Medicine, University of Rome "Sapienza", C.so della Repubblica 79, 04100 Latina, Italy

²IRCCS Neuromed, Località Camerelle, 86077 Pozzilli, Italy

*Corresponding author: Mariangela Peruzzi, MD, Department of Medical-Surgical Science and Biotechnologies, Faculty of Pharmacy and Medicine, University of Rome "Sapienza", C.so della Repubblica 79, 04100 Latina, Italy, E-mail: mariangela.peruzzi@uniroma1.it

Keywords : Ventricular remodeling; Myocardial infarction; Inflammation

Received Date: 17 May 2014

Accepted Date: 20 May 2014

Published Date: 24 May 2014

Despite the striking improvements recently achieved in the diagnosis and treatment of acute myocardial infarction (AMI), this condition remains a leading cause of death worldwide [1]. The term "ventricular remodeling" refers to changes in ventricular geometry (dilation, sphericity, wall thinning) and stiffness, as well as molecular and functional changes including both cardiomyocytes, other cells of the heart and extracellular matrix [2,3]. As a result, over recent years much interest has been devoted to understanding the role and the pathways involved in the setting of the inflammation in AMI as well as in overload conditions [4] but to date, however, there is a lack of real anti-inflammatory treatments for these conditions. This topic has been recently highlighted by Seropian et al., in a detailed paper [5] focusing on anti-inflammatory strategies for ventricular remodelling following ST-segment elevation myocardial infarction (STEMI), concluding that more studies are needed to determine the most appropriate strategies to restore the inflammatory balance and ameliorate remodelling after acute myocardial infarction (AMI). This holds even truer given the established heterogeneity among different anti-inflammatory agents, as clearly demonstrated in many different pathophysiologic conditions [5,6]. We agree that this entire process should be considered as a complex biological *milieu* finally evolving into maladaptive remodelling, with the result to be still a slippery therapeutic target. Nonetheless, the report raises additional issues that need to be addressed in order to enlighten the corresponding hidden side of the moon.

Citation: Peruzzi M, Biondi-Zoccai G, Marullo AG, Barretta A, Vitulli P, et al. (2014) New Therapeutic Strategies for Ventricular Remodeling in Acute Myocardial Infarction and Pressure Overload: The Long Way to Heaven. *Enliven: J Anesthesiol Crit Care Med* 1(1): 007.

Copyright: © 2014 Dr. Mariangela Peruzzi. This is an Open Access article published and distributed under the terms of the Creative Commons Attribution License, that permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

First, the recent demonstration that cardiomyocytes are not terminally differentiated cells with the capacity to re-enter the cell cycle even in AMI models and the finding of a cardiac stem cell (CSCs)-associated paracrine enhancement in tissue preservation and recruitment of endogenous repair [7,8], strongly suggest that CSCs also might be involved in determining which patients respond favorably or not to early reperfusion strategy in routine clinical practice. The concept of the heart considered as a "dynamic environment" responding to multifaceted stimuli seems also to be corroborated by several studies concerning mechanical unloading achieved by Left Ventricular Assist Devices (LVAD) [9,10] in which CSCs seem to significantly contribute in the recovery of cardiac function and in the substantial reverse remodeling occurring during LVAD support. Last a key role to be fully exploited in the modulation of heart inflammation toward anti-remodeling strategies maybe represented by the synergistic combination of cardiac stem cells therapy and tissue engineering (TE): this hopeful union seems thus to boost the sole protective role achieved from stem cells or TE in limiting myocardial remodeling [3,11]. It seems likely that, stem cell therapy joined with TE technology, will occupy within the next decade a significant place in the treatment of several cardiovascular diseases. Accordingly an accurate intertwining of muscle/extracellular matrix re-growth, inflammation, and angiogenesis, coupled with changes in cardiac metabolic profile, may be pivotal to ensure adaptive remodelling in both conditions, AMI as well as overload conditions CSCs [12].

Once more, focusing deeply on this topic, it is noteworthy to emphasize the key role of other important mediators in the recovery of cardiac function following AMI and overload conditions: cytokines, integrins, proapoptotic genes, MMPs, PI3K, complement cascade, reactive oxygen species (ROS), micro-RNA [13] mediating post-transcriptional gene silencing and last, the possible role of epigenomic changes that can explain a characteristic hallmark of heart failure (HF), i.e. altered gene expression. The cardiac environment under conditions of stress such as ischemia and overload may therefore promote epigenomic changes with a subsequent plasticity in gene expression and phenotype leading to hell as well as to heaven.

In conclusion, all these fields of research arise important questions of potential clinical impact as this complex picture is strongly supportive of a pivotal role of many factors in establishing an adequate and necessary inflammatory response to several pathological conditions.

References

1. National Heart Lung and Blood Institute (2012) Morbidity and Mortality: 2012 Chart Book on Cardiovascular and Lung Diseases. Bethesda, MD: NIH.
2. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. *J Am Coll Cardiol* 35: 569-582.
3. Gaetani R, Rizzitelli G, Chimenti I, Barile L, Forte E, et al. (2010) Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application. *J Cell Mol Med* 14: 1071-1077.
4. Frangogiannis NG (2014) The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. *J Cardiovasc Pharmacol* 63: 185-195.
5. Seropian IM, Toldo S, Van Tassel BW, Abbate A (2014) Anti-Inflammatory Strategies for Ventricular Remodeling Following ST-Segment Elevation Acute Myocardial Infarction. *J Am Coll Cardiol* 63: 1593-1603.
6. Peruzzi M, Colombo D, De Falco E, Chimenti I, Abbate A, et al. (2014) Biologic therapy for psoriatic arthritis or moderate to severe plaque psoriasis: systematic review with pairwise and network meta-analysis. *Int J Stats Med Res* 3: 74-87.
7. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, et al. (2009) Evidence for cardiomyocyte renewal in humans. *Science* 324: 98-102.
8. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, et al. (2010) Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circ Res* 106: 971-980.
9. Drakos SG, Wever-Pinzon O, Selzman CH, Gilbert EM, Alharethi R, et al. (2013) Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. *J Am Coll Cardiol* 61: 1985-1994.
10. Marullo AG, Peruzzi M, Cavarretta E, Biondi-Zoccai G, Frati G (2013) Left ventricular assist devices in chronic heart failure: more questions than answers? *J Am Coll Cardiol* 62: 2257.
11. Chimenti I, Rizzitelli G, Gaetani R, Angelini F, Ionta V, et al. (2011) Human cardiosphere-seeded gelatin and collagen scaffolds as cardiogenic engineered bioconstructs. *Biomaterials* 32: 9271-9281.
12. Carnevale D, Cifelli G, Mascio G, Madonna M, Sbroggiò M, et al. (2011) Placental growth factor regulates cardiac inflammation through the tissue inhibitor of metalloproteinases-3/tumor necrosis factor- α -converting enzyme axis: crucial role for adaptive cardiac remodeling during cardiac pressure overload. *Circulation* 124: 1337-1350.
13. Condorelli G, Latronico MV, Cavarretta E (2014) microRNAs in cardiovascular diseases: current knowledge and the road ahead. *J Am Coll Cardiol Pii*: S0735-1097(14)01108-011085.

Besides the discrepancies among different evidences reported about the efficacy of cardiac anti-inflammatory therapies, we believe that it will be paramount to carry out a gnoseological step-back to identify a representative cohort of patients in order to provide new important insights into physician patterns of practice related to recovery therapies, allowing customized strategies to be targeted to each specific patient.

Funding/conflicts of interest : Prof. Frati holds two patents concerning stem cells in cardiovascular medicine (Patent: Italy-RM2003A00037631.07.2003 - WO2005012510, 2005-02-10- Giacomello A, Messina E, Battaglia M, Frati G, Method for the isolation and expansion of cardiac stem cells from biopsy

Patent: US 20120021019 A1, 2012-01-26 - Giacomello A., Messina E., Battaglia M., Frati G, Cardiac stem cell populations for repair of cardiac tissue- Owner: University of Rome "Sapienza").

Submit your manuscript at
<http://enlivenarchive.org/submit-manuscript.php>

New initiative of Enliven Archive

Apart from providing HTML, PDF versions; we also provide **video version** and deposit the videos in about 15 freely accessible social network sites that promote videos which in turn will aid in rapid circulation of articles published with us.